Factory 99% Palbociclib Powder CAS 571190-30-2 Chemical Intermediate Palbociclib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A819
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Palbociclib
• CAS: 571190-30-2
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Palbociclib
Appearance	White Powder
CAS NO.	571190-30-2
Storage	Keep in a cool, dry, dark location

 

Palbociclib, also known as PD 0332991, is an orally available, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It belongs to a class of pyridopyrimidine-derived compounds and exhibits potential antineoplastic activity.

 

1. Breast Cancer Treatment: Palbociclib is primarily used in the treatment of estrogen receptor-positive (ER+) and human epidermal receptor 2-negative (HER2-) advanced or metastatic breast cancer.
2. Combination Therapy: It is often administered in combination with other therapies, such as endocrine therapy or chemotherapy, to enhance the treatment efficacy.
3. Initial Therapy Option: For postmenopausal women with ER+/HER2- advanced breast cancer, Palbociclib can be used as an initial therapy option in combination with endocrine therapy.

1. Selective CDK4/6 Inhibition: Palbociclib selectively inhibits the activity of CDK4 and CDK6, which are key regulators of the cell cycle. This inhibition leads to the arrest of cancer cell proliferation.
2. Cell Cycle Control Restoration: By blocking the activity of CDK4/6, Palbociclib helps restore normal cell cycle control, thereby preventing the uncontrolled growth and division of cancer cells.
3. Enhanced Therapeutic Efficacy: In combination with other therapies, Palbociclib has been shown to enhance the overall therapeutic efficacy in treating ER+/HER2- advanced breast cancer, prolonging progression-free survival and improving patient outcomes.